In recent days, Moderna and Merck reported five-year Phase 2b data showing that their personalized mRNA melanoma vaccine ...

A study finds that an mRNA vaccine is highly effective at preventing recurrence of this dangerous skin cancer, when used in ...

Many people first learned about mRNA vaccines during the coronavirus pandemic, when the companies Pfizer-BioNTech and Moderna released their COVID-19 vaccines. The Pfizer-BioNTech shot was the first ...

Moderna (NasdaqGS:MRNA) has expanded its collaboration with CEPI to accelerate development of an mRNA vaccine targeting ...

Lynch syndrome is an inherited condition affecting 1 in 300 people that causes lifetime cancer risk of up to 80%[1]The ...

BioNTech co-founders Dr. Ugur Sahin and Dr. Ozlem Tureci in its headquarters in Germany on Jan. 3.Photograph by Dina Litovsky—Redux for TIME “No!” The doctor snapped. “Look at me!” I had been staring ...

Moderna’s mRNA-centric business is in conflict with the U.S. government’s shifting views on mRNA technology, and analysts say that’s a risk. The biotech announced Tuesday evening that in a rare move, ...

Since 2023, Moderna and Korea University have been developing a new mRNA vaccine for hantavirus. The work has been promising so far, but a finished product isn't likely coming any time soon.

Moderna (NASDAQ:MRNA) announced on Monday a new collaboration with an international health organization aimed at accelerating ...

The biotech company said the FDA won't review its flu vaccine, in the latest hit to mRNA development As COVID-19 vaccine sales dwindle, pressure on Moderna to grow its business has increased.